| Mana Rao, MD | |
|
2015 Grand Concourse, Bronx, NY 10453-4303 | |
| (718) 299-7295 | |
| (718) 299-6797 |
| Full Name | Mana Rao |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Infectious Disease |
| Location | 2015 Grand Concourse, Bronx, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003162686 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 289097 (New York) | Primary |
| Entity Name | Essen Medical Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366418709 PECOS PAC ID: 1759353501 Enrollment ID: O20040811000885 |
News Archive
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
UT Southwestern researchers have uncovered new clues about how gut bacteria and the body's circadian clock work together to promote body fat accumulation.
At the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) to be held Oct. 28-Nov. 1, in Okinawa, Japan, University of Cincinnati researchers will present four papers, including one detailing improvements in rare cell isolation and one detailing improvements, in terms of cost and time, of common blood tests.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
New research released from the University of Colorado Anschutz Medical Campus proposes that Alzheimer's disease may be driven by the overactivation of fructose made in the brain.
› Verified 3 days ago
| Entity Name | House Call Medical Services Of New York Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851345946 PECOS PAC ID: 2264517754 Enrollment ID: O20080307000427 |
News Archive
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
UT Southwestern researchers have uncovered new clues about how gut bacteria and the body's circadian clock work together to promote body fat accumulation.
At the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) to be held Oct. 28-Nov. 1, in Okinawa, Japan, University of Cincinnati researchers will present four papers, including one detailing improvements in rare cell isolation and one detailing improvements, in terms of cost and time, of common blood tests.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
New research released from the University of Colorado Anschutz Medical Campus proposes that Alzheimer's disease may be driven by the overactivation of fructose made in the brain.
› Verified 3 days ago
| Entity Name | Essen Medical Urgicare, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841607298 PECOS PAC ID: 4385960897 Enrollment ID: O20150227000903 |
News Archive
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
UT Southwestern researchers have uncovered new clues about how gut bacteria and the body's circadian clock work together to promote body fat accumulation.
At the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) to be held Oct. 28-Nov. 1, in Okinawa, Japan, University of Cincinnati researchers will present four papers, including one detailing improvements in rare cell isolation and one detailing improvements, in terms of cost and time, of common blood tests.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
New research released from the University of Colorado Anschutz Medical Campus proposes that Alzheimer's disease may be driven by the overactivation of fructose made in the brain.
› Verified 3 days ago
| Entity Name | Bronx Medical Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356726087 PECOS PAC ID: 9739496100 Enrollment ID: O20150917000004 |
News Archive
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
UT Southwestern researchers have uncovered new clues about how gut bacteria and the body's circadian clock work together to promote body fat accumulation.
At the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) to be held Oct. 28-Nov. 1, in Okinawa, Japan, University of Cincinnati researchers will present four papers, including one detailing improvements in rare cell isolation and one detailing improvements, in terms of cost and time, of common blood tests.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
New research released from the University of Colorado Anschutz Medical Campus proposes that Alzheimer's disease may be driven by the overactivation of fructose made in the brain.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mana Rao, MD 1434 Williamsbridge Rd Fl 2, Bronx, NY 10461-2507 Ph: (718) 618-0401 | Mana Rao, MD 2015 Grand Concourse, Bronx, NY 10453-4303 Ph: (718) 299-7295 |
News Archive
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
UT Southwestern researchers have uncovered new clues about how gut bacteria and the body's circadian clock work together to promote body fat accumulation.
At the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) to be held Oct. 28-Nov. 1, in Okinawa, Japan, University of Cincinnati researchers will present four papers, including one detailing improvements in rare cell isolation and one detailing improvements, in terms of cost and time, of common blood tests.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
New research released from the University of Colorado Anschutz Medical Campus proposes that Alzheimer's disease may be driven by the overactivation of fructose made in the brain.
› Verified 3 days ago
Selina Sultana Zaman, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 600 E 233rd St, Bronx, NY 10466 Phone: 718-920-9000 | |
Dr. Jyothi B Kudakandira, M.D Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1650 Grand Concourse, Bronx, NY 10457 Phone: 718-960-1234 | |
Dr. Keshav Teelucksingh, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2015 Grand Concourse, Bronx, NY 10453 Phone: 718-299-7295 Fax: 718-299-6797 | |
Tannaz Iranpour Boroujeni, M.D Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 600 E 233rd St, Bronx, NY 10466 Phone: 617-840-0110 | |
Heather Root, MD Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 111 E 210th St, Bronx, NY 10467 Phone: 718-920-8592 Fax: 718-405-0610 | |
Benjamin Tuttle Hayes, MD Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 305 E 161st St, Bronx, NY 10451 Phone: 718-579-2500 Fax: 718-579-2599 |